A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Public ClinicalTrials.gov record NCT02118337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Study identification
- NCT ID
- NCT02118337
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 97 participants
Conditions and interventions
Interventions
- Durvalumab Biological
- MEDI0680 Biological
- Nivolumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2014
- Primary completion
- Mar 16, 2020
- Completion
- Mar 16, 2020
- Last update posted
- May 31, 2021
2014 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Overland Park | Kansas | 66209 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Hershey | Pennsylvania | 17033-0850 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02118337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2021 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02118337 live on ClinicalTrials.gov.